Proteasome inhibitor therapy for antibody-mediated rejection

Area of Science:

• Transplantation immunology
• Pharmacology
• Nephrology

Background:

• Antibody-mediated rejection (AMR) remains a significant threat to renal allograft survival.
• Traditional AMR therapies yield inconsistent results and fail to eliminate antibody-producing plasma cells.

Purpose of the Study:

• To evaluate the efficacy of bortezomib, a proteasome inhibitor, as a targeted therapy for AMR.
• To assess bortezomib's potential in reducing anti-HLA antibody levels and improving transplant outcomes.

Main Methods:

• Bortezomib, a proteasome inhibitor (PI), was administered to kidney transplant recipients with AMR.
• Subsequent studies included refractory AMR, primary AMR therapy, and expanded to heart transplant recipients.
• A prospective trial investigated bortezomib's effect on anti-HLA antibody levels.

Main Results:

• Bortezomib demonstrated efficacy in treating both refractory and primary AMR.
• The therapy was effective in adult and pediatric heart transplant recipients.
• Bortezomib alone significantly reduced anti-HLA antibody levels in a desensitization trial.

Conclusions:

• Bortezomib represents a novel, effective plasma cell-targeted therapy for AMR.
• Proteasome inhibition shows significant potential in overcoming humoral barriers in transplantation.
• Further strategies involving proteasome inhibition may enhance synergistic effects for AMR treatment.